In conclusion, we have demonstrated that combined (LY and CUR) treatment can synergistically inhibit the progression of BPH by reducing the expression of inflammatory factors and cell proliferation marker Ki-67 and regulating the hormone level. The gene discussed is MKI67; the disease is benign prostatic hyperplasia.